File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Book Chapter: Allogeneic Hematopoietic Stem Cell Transplantation for MDS and CMML: When and How?
| Title | Allogeneic Hematopoietic Stem Cell Transplantation for MDS and CMML: When and How? |
|---|---|
| Authors | |
| Issue Date | 28-Sep-2023 |
| Publisher | Springer Nature Singapore |
| Abstract | Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative treatment in both MDS and CMML. In MDS, there is an increasing prevalence of high-risk MDS undergoing HSCT, whereas only a selected group of patients with low-risk MDS will receive standard or low-intensity HSCT for permanent disease eradication. Other than the disease risk itself, patients’ age, comorbidities, performance status, and disease risk act as limiting factors to the efficacy of HSCT in both MDS and CMML patients. Hence, not all patients are eligible for transplantation. Prognostic markers should be carefully evaluated before considering HSCT. In this chapter, we review the indications of allo-HSCT in MDS and CMML. |
| Persistent Identifier | http://hdl.handle.net/10722/341851 |
| ISBN |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Gill, Harinder | - |
| dc.contributor.author | Yung, Yammy | - |
| dc.contributor.author | Chu, Cherry | - |
| dc.contributor.author | Yip, Amber | - |
| dc.date.accessioned | 2024-03-26T05:37:41Z | - |
| dc.date.available | 2024-03-26T05:37:41Z | - |
| dc.date.issued | 2023-09-28 | - |
| dc.identifier.isbn | 9789819938094 | - |
| dc.identifier.uri | http://hdl.handle.net/10722/341851 | - |
| dc.description.abstract | <p>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative treatment in both MDS and CMML. In MDS, there is an increasing prevalence of high-risk MDS undergoing HSCT, whereas only a selected group of patients with low-risk MDS will receive standard or low-intensity HSCT for permanent disease eradication. Other than the disease risk itself, patients’ age, comorbidities, performance status, and disease risk act as limiting factors to the efficacy of HSCT in both MDS and CMML patients. Hence, not all patients are eligible for transplantation. Prognostic markers should be carefully evaluated before considering HSCT. In this chapter, we review the indications of allo-HSCT in MDS and CMML.<br></p> | - |
| dc.language | eng | - |
| dc.publisher | Springer Nature Singapore | - |
| dc.relation.ispartof | Pathogenesis and Treatment of Leukemia | - |
| dc.title | Allogeneic Hematopoietic Stem Cell Transplantation for MDS and CMML: When and How? | - |
| dc.type | Book_Chapter | - |
| dc.identifier.doi | 10.1007/978-981-99-3810-0_34 | - |
| dc.identifier.eisbn | 9789819938100 | - |